Are immune checkpoint inhibitors safe for patients with Hepatitis B Virus Infection and solid tumors?
Immune checkpoint inhibitors (ICIs) are a type of cancer immunotherapy that helps the immune system attack tumors. For patients with hepatitis B virus (HBV) infection and solid tumors, doctors have been cautious because ICIs could potentially trigger HBV reactivation (the virus becoming active again). Current evidence suggests that ICIs are generally safe in this setting, especially when HBV is well-controlled with antiviral therapy. However, the risk of reactivation is not zero, and careful monitoring is needed.
What the research says
A narrative review on ICIs in patients with viral infections and solid tumors notes that patients with HBV who receive ICIs may regain antitumor immune function and sometimes show improved viral control, but the risk of viral reactivation remains a concern, particularly when immune-related adverse events require immunosuppressive treatment 3. A phase Ib study of nivolumab (a PD-1 inhibitor) in virally suppressed chronic HBV patients found no grade 3 or 4 adverse events and no serious adverse events, with some patients experiencing declines in hepatitis B surface antigen levels 10. This suggests that ICIs can be used safely when HBV is suppressed. However, a case report of a patient with resolved HBV who developed severe immune-mediated hepatitis during pembrolizumab treatment highlights that ICIs can cause liver inflammation, which may be more complex in HBV patients 11. Additionally, a study on HBV reactivation after TACE (a liver cancer treatment) found that absence of antiviral therapy increased reactivation risk 2, underscoring the importance of antiviral prophylaxis in HBV patients undergoing immunosuppressive therapies. Overall, the evidence indicates that ICIs are safe for HBV patients with solid tumors when viral load is suppressed, but reactivation risk exists, especially during immunosuppression for immune-related adverse events.
What to ask your doctor
- Should I be on antiviral therapy before starting immune checkpoint inhibitor treatment?
- How often will my HBV viral load and liver function be monitored during ICI therapy?
- What are the signs of HBV reactivation or immune-mediated hepatitis that I should watch for?
- If I develop immune-related side effects that need steroids, will that increase my HBV reactivation risk?
- Is there any difference in safety between different types of ICIs (e.g., PD-1 vs. CTLA-4 inhibitors) for HBV patients?
This question is drawn from common patient questions about Allergy & Immunology and answered using cited medical research. We do not provide individualized advice.